2023

Karamouza, E. et al. (2023) CA-125 early dynamics to predict overall survival in women with newly diagnosed advanced ovarian cancer based on meta-analysis data. Cancers, 15(6), 1823. (doi: 10.3390/cancers15061823) (PMID:36980708) (PMCID:PMC10047009)

2022

Gershenson, D. M. et al. (2022) Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet, 399(10324), pp. 541-553. (doi: 10.1016/S0140-6736(21)02175-9) (PMID:35123694) (PMCID:PMC8819271)

Love, S. B. et al. (2022) Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units. Trials, 23, 757. (doi: 10.1186/s13063-022-06680-4) (PMID:36068599) (PMCID:PMC9449272)

2021

Edmondson, R. J. et al. (2021) Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903). Gynecologic Oncology, 163(3), pp. 524-530. (doi: 10.1016/j.ygyno.2021.09.010) (PMID:34625284)

2019

Gershenson, D.M. et al. (2019) A randomized phase II/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer. Annals of Oncology, 30(Suppl5), v897-v898. (doi: 10.1093/annonc/mdz394.058)

Zhou, C. et al. (2019) Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology, 85(8), pp. 1781-1789. (doi: 10.1111/bcp.13965) (PMID:30980733) (PMCID:PMC6624436)

Mileshkin, L. et al. (2019) Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903. Gynecologic Oncology, 154(1), pp. 29-37. (doi: 10.1016/j.ygyno.2019.05.007) (PMID:31130288)

2018

Kelemen, L. E. et al. (2018) rs495139 in the TYMS-ENOSF1 region and risk of ovarian carcinoma of mucinous histology. International Journal of Molecular Sciences, 19(9), 2473. (doi: 10.3390/ijms19092473) (PMID:30134598) (PMCID:PMC6163881)

2017

Kar, S. P. et al. (2017) Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 116(4), pp. 524-535. (doi: 10.1038/bjc.2016.426) (PMID:28103614) (PMCID:PMC5318969)

2016

Hampras, S. S. et al. (2016) Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 7(43), pp. 69097-69110. (doi: 10.18632/oncotarget.10215) (PMID:27533245)

2015

Johnatty, S. E. et al. (2015) Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 21(23), pp. 5264-5276. (doi: 10.1158/1078-0432.CCR-15-0632) (PMID:26152742) (PMCID:PMC4624261)

Symonds, R. P. et al. (2015) Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology, 16(15), pp. 1515-1524. (doi: 10.1016/S1470-2045(15)00220-X) (PMID:26474517) (PMCID:PMC4705431)

Kar, S. P. et al. (2015) Network-based integration of GWAS and gene expression identifies a HOX-centric network associated with serous ovarian cancer risk. Cancer Epidemiology, Biomarkers and Prevention, 24(10), pp. 1574-1584. (doi: 10.1158/1055-9965.epi-14-1270) (PMID:26209509)

Lee, A. W. et al. (2015) Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. Gynecologic Oncology, 136(3), pp. 542-548. (doi: 10.1016/j.ygyno.2014.12.017) (PMID:25528498)

Chornokur, G. et al. (2015) Common genetic variation in cellular transport genes and epithelial ovarian cancer (EOC) risk. PLoS ONE, 10(6), e0128106. (doi: 10.1371/journal.pone.0128106) (PMID:26091520) (PMCID:PMC4474865)

Kelemen, L.E. et al. (2015) Genome-wide significant risk associations for mucinous ovarian carcinoma. Nature Genetics, 47(8), pp. 888-897. (doi: 10.1038/ng.3336) (PMID:26075790) (PMCID:PMC4520768)

Kuchenbaecker, K. B. et al. (2015) Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 47(2), pp. 164-171. (doi: 10.1038/ng.3185)

2014

Kelemen, L. E. et al. (2014) Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition and Food Research, 58(10), pp. 2023-2035. (doi: 10.1002/mnfr.201400068) (PMID:25066213)

2013

O'Cathail, S. M. , Shaboodien, R., Mahmoud, S., Carty, K., O'Sullivan, P., Blagden, S., Gabra, H., Whear, S., Kwon, J. S. and Agarwal, R. (2013) Intravenous versus oral dexamethasone premedication in preventing paclitaxel infusion hypersensitivity reactions in gynecological malignancies. International Journal of Gynecologic Cancer, 23(7), pp. 1318-1325. (doi: 10.1097/IGC.0b013e31829f1799) (PMID:23907557)

2008

Vasey, P.A. et al. (2008) A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. British Journal of Cancer, 98(11), pp. 1774-1780. (doi: 10.1038/sj.bjc.6604371.)

Articles

Karamouza, E. et al. (2023) CA-125 early dynamics to predict overall survival in women with newly diagnosed advanced ovarian cancer based on meta-analysis data. Cancers, 15(6), 1823. (doi: 10.3390/cancers15061823) (PMID:36980708) (PMCID:PMC10047009)

Gershenson, D. M. et al. (2022) Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet, 399(10324), pp. 541-553. (doi: 10.1016/S0140-6736(21)02175-9) (PMID:35123694) (PMCID:PMC8819271)

Love, S. B. et al. (2022) Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units. Trials, 23, 757. (doi: 10.1186/s13063-022-06680-4) (PMID:36068599) (PMCID:PMC9449272)

Edmondson, R. J. et al. (2021) Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903). Gynecologic Oncology, 163(3), pp. 524-530. (doi: 10.1016/j.ygyno.2021.09.010) (PMID:34625284)

Gershenson, D.M. et al. (2019) A randomized phase II/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer. Annals of Oncology, 30(Suppl5), v897-v898. (doi: 10.1093/annonc/mdz394.058)

Zhou, C. et al. (2019) Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology, 85(8), pp. 1781-1789. (doi: 10.1111/bcp.13965) (PMID:30980733) (PMCID:PMC6624436)

Mileshkin, L. et al. (2019) Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903. Gynecologic Oncology, 154(1), pp. 29-37. (doi: 10.1016/j.ygyno.2019.05.007) (PMID:31130288)

Kelemen, L. E. et al. (2018) rs495139 in the TYMS-ENOSF1 region and risk of ovarian carcinoma of mucinous histology. International Journal of Molecular Sciences, 19(9), 2473. (doi: 10.3390/ijms19092473) (PMID:30134598) (PMCID:PMC6163881)

Kar, S. P. et al. (2017) Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 116(4), pp. 524-535. (doi: 10.1038/bjc.2016.426) (PMID:28103614) (PMCID:PMC5318969)

Hampras, S. S. et al. (2016) Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 7(43), pp. 69097-69110. (doi: 10.18632/oncotarget.10215) (PMID:27533245)

Johnatty, S. E. et al. (2015) Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 21(23), pp. 5264-5276. (doi: 10.1158/1078-0432.CCR-15-0632) (PMID:26152742) (PMCID:PMC4624261)

Symonds, R. P. et al. (2015) Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology, 16(15), pp. 1515-1524. (doi: 10.1016/S1470-2045(15)00220-X) (PMID:26474517) (PMCID:PMC4705431)

Kar, S. P. et al. (2015) Network-based integration of GWAS and gene expression identifies a HOX-centric network associated with serous ovarian cancer risk. Cancer Epidemiology, Biomarkers and Prevention, 24(10), pp. 1574-1584. (doi: 10.1158/1055-9965.epi-14-1270) (PMID:26209509)

Lee, A. W. et al. (2015) Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. Gynecologic Oncology, 136(3), pp. 542-548. (doi: 10.1016/j.ygyno.2014.12.017) (PMID:25528498)

Chornokur, G. et al. (2015) Common genetic variation in cellular transport genes and epithelial ovarian cancer (EOC) risk. PLoS ONE, 10(6), e0128106. (doi: 10.1371/journal.pone.0128106) (PMID:26091520) (PMCID:PMC4474865)

Kelemen, L.E. et al. (2015) Genome-wide significant risk associations for mucinous ovarian carcinoma. Nature Genetics, 47(8), pp. 888-897. (doi: 10.1038/ng.3336) (PMID:26075790) (PMCID:PMC4520768)

Kuchenbaecker, K. B. et al. (2015) Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 47(2), pp. 164-171. (doi: 10.1038/ng.3185)

Kelemen, L. E. et al. (2014) Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition and Food Research, 58(10), pp. 2023-2035. (doi: 10.1002/mnfr.201400068) (PMID:25066213)

O'Cathail, S. M. , Shaboodien, R., Mahmoud, S., Carty, K., O'Sullivan, P., Blagden, S., Gabra, H., Whear, S., Kwon, J. S. and Agarwal, R. (2013) Intravenous versus oral dexamethasone premedication in preventing paclitaxel infusion hypersensitivity reactions in gynecological malignancies. International Journal of Gynecologic Cancer, 23(7), pp. 1318-1325. (doi: 10.1097/IGC.0b013e31829f1799) (PMID:23907557)

Vasey, P.A. et al. (2008) A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. British Journal of Cancer, 98(11), pp. 1774-1780. (doi: 10.1038/sj.bjc.6604371.)